Magnus Bäck,Maciej Banach,Frieder Braunschweig et al.
Magnus Bäck et al.
Cilostazol for heart rate increase in atrial fibrillation with slow ventricular response: an exploratory randomized controlled trial [0.03%]
西洛他唑对心房颤动伴缓慢室性反应患者的心率增快作用的一项探索性随机对照试验
Gabriela Hinkelmann Berbert,Rogerio Braga Andalaft,Bruno Pereira Valdigem et al.
Gabriela Hinkelmann Berbert et al.
Aims: Atrial fibrillation (AF) with slow ventricular response is a clinically challenging condition, particularly in elderly patients with multiple comorbidities. Current therapeutic options for the chronic pharmacologica...
Cost-effectiveness of combined veno-arterial extracorporeal membrane oxygenation and Impella support (ECPELLA) in infarct-related cardiogenic shock [0.03%]
联合使用静脉动脉体外膜氧合和Impella心室辅助装置支持治疗急性心肌梗死合并心源性休克的成本效益分析
Priyanka Boettger,Andrija Matetic,Jamschid Sedighi et al.
Priyanka Boettger et al.
Aims: Cardiogenic shock carries high early mortality. Combined veno-arterial extracorporeal membrane oxygenation and Impella support (ECPELLA) may improve outcomes but is costly and unevenly available across Europe. Its i...
Predicted cardiovascular risk reduction with tirzepatide vs. semaglutide: interpretative considerations from the SURMOUNT-5 post hoc analysis [0.03%]
SURMOUNT-5事后分析中司美格鲁肽和 tirzepatide预测的心血管风险降低：解释性考虑因素
Samit Ghosal,Binayak Sinha
Samit Ghosal
International expert consensus on a structured approach to training for cryoballoon-based ablation for atrial fibrillation procedure using performance metrics [0.03%]
国际冷冻球囊型导管消融治疗房颤结构化培训专家共识及相关性能指标的确立
Serge Boveda,Carlo de Asmundis,Andreas Metzner et al.
Serge Boveda et al.
Aims: Training on cryoballoon-based ablation for atrial fibrillation (CBA-AF) procedures usually takes place in vivo, and methods vary across countries/institutions. We sought to identify objective performance metrics tha...
Soluble urokinase plasminogen activator receptor for risk stratification from undifferentiated acute chest pain through to convalescence after acute coronary syndromes [0.03%]
可溶性尿激酶型纤溶酶原激活物受体用于鉴别急性非 ST 段抬高型心脏病患者血管成形术的获益与风险
Taylor Keys,Charlotte Greer,Philip D Adamson et al.
Taylor Keys et al.
Aims: The performance of plasma soluble urokinase plasminogen activator receptor (suPAR) for prediction of heart failure (HF) readmission or death within 5 years was assessed in patients incurring (i) initially undifferen...
Early aortic valve intervention in asymptomatic severe aortic stenosis: a clinical dilemma in evolution [0.03%]
无症状重度主动脉瓣狭窄的早期手术干预：一个临床难题的发展过程
Patrizio Lancellotti,Augustin Coisne,Bernard Cosyns et al.
Patrizio Lancellotti et al.
The management of asymptomatic severe aortic stenosis (AS) has traditionally relied on watchful waiting until the onset of symptoms or left ventricular dysfunction. However, the FDA's approval of transcatheter aortic valve replacement (TAVR...
Population-level cardiovascular risk prediction models including biochemical predictors in 800 000 individuals [0.03%]
基于生化标志物的80万人大规模心血管风险预测模型
Bruno Batinica,Suneela Mehta,Jingyuan Liang et al.
Bruno Batinica et al.
Aims: Most countries lack the clinical cohort data required to create cardiovascular disease (CVD) risk prediction models and rely on models developed elsewhere. However, individual-person linkage of health administrative...
Monitored anaesthesia care without endotracheal intubation and general anaesthesia in pulsed field atrial fibrillation ablation [0.03%]
监测麻醉（未插入气管内导管）和全身麻醉在脉冲场房颤消融中的应用
Weijia Wang,Swecha Goel,Susan J Estrada et al.
Weijia Wang et al.
Aims: Pulsed field ablation for atrial fibrillation offers shorter procedural times and improved safety compared with thermal ablation, but the optimal anaesthesia strategy remains uncertain. Most centres in the USA use g...
Rate control treatment with calcium channel blockers and beta blockers for patients with atrial fibrillation: a systematic review and meta-analysis [0.03%]
房颤患者心室率控制的钙拮抗剂和β受体阻滞剂治疗：系统评价和meta分析
Tim Koldenhof,Barzi Gareb,Marcelle D Smit et al.
Tim Koldenhof et al.
Aims: Controlling heart rate is a key objective in atrial fibrillation (AF) management, commonly achieved with beta blockers or non-dihydropyridine calcium channel blockers, both class I guideline recommendations. However...